Top

BMC Cancer

Published in:

Open Access 01-12-2019 | Metastasis | Research article

Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis

Authors: Jian Xu, Gang Li, Shi Miao Zhu, Qi Liang Cai, Zhun Wang, Xiong Yang, Hong Tan Zhang, Yuan Jie Niu

Published in: BMC Cancer | Issue 1/2019

Abstract

Background

Chemotherapy may be a valuable treatment option as neoadjuvant treatment for locally advanced penile cancer according to some previous studies, but the rarity of the sample and the Lack of large-scale clinical trials hampered the attempt to establish a solid evidence base for its routine use. The purpose of this study was to evaluate the efficacy of the neoadjuvant chemotherapy combined with a ITP regimen including docetaxel, cisplatin and ifosfamide for treating advanced penile cancer patients.

Methods

A total of 19 patients who were classified into advanced penile cancer (PN3) received neoadjuvant chemotherapy of ITP regimen from June 2009 to June 2016 in our hospital.

Results

After chemotherapy 12 patients had a partial response (PR), 5 had stable disease (SD) and progressive disease (PD) in 2 cases. The 12 responders underwent penectomy, bilateral inguinal lymphadenectomy (ILND) and pelvic lymph node dissection (LPLND). In contrast, 7 cases who were non-responsive received palliative local radiotherapy. After a median follow-up of 30.6 months, there was statistically significant improvement in median PFS and OS among patients who experienced an objective response to neoadjuvant chemotherapy (group A) compared with those patients who did not respond to chemotherapy (group B) (log-rank test; P < 0.001).

Conclusion

Neoadjuvant docetaxel, cisplatin and ifosfamide chemotherapy gave 63% (12/19) of patients who were diagnosed with stage n3 penile cancer the chance of radical resection of metastases, and their OS and PFS were significantly higher than those who could not be operated on and the therapeutic dose, toxic and side effects are acceptable in the Chinese Han population. Therefore, neoadjuvant ITP chemotherapy in the treatment of stage T3 penile cancer patients may have cheerful prospects in the Chinese Han population.

Mobilio G, Ficarra V. Genital treatment of penile carcinoma. Curr Opin Urol. 2001;11(3):299–304.CrossRef

Rando Sous A, Pérez-Utrilla Pérez M, Aguilera Bazán A, Tabernero Gomez A, Cisneros Ledo J, De la Peña Barthel J. A review of penile cancer. Adv Urol. 2009:415062. https://doi.org/10.1155/2009/415062.CrossRef

Pizzocaro, G., Algaba, F., Horenblas, S., Solsona, E., Tana, S., Van Der Poel, H., . . . European Association of Urology Guidelines Group on Penile, Cancer. EAU penile cancer guidelines 2009. Eur Urol. 2010;57(6):1002–12. https://doi.org/10.1016/j.eururo.2010.01.039.CrossRef

Nicholson, S., Hall, E., Harland, S. J., Chester, J. D., Pickering, L., Barber, J., . . . Bahl, A. (2013). Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer, 109(10), 2554–2559. doi: https://doi.org/10.1038/bjc.2013.620.CrossRefPubMedPubMedCentral

Deem S, Keane T, Bhavsar R, El-Zawahary A, Savage S. Contemporary diagnosis and management of squamous cell carcinoma (SCC) of the penis. BJU Int. 2011;108(9):1378–92. https://doi.org/10.1111/j.1464-410X.2011.10647.x.CrossRefPubMed

Culkin DJ, Beer TM. Advanced penile carcinoma. J Urol. 2003;170(2 Pt 1):359–65. https://doi.org/10.1097/01.ju.0000062829.43654.5e.CrossRefPubMed

Haas, G. P., Blumenstein, B. A., Gagliano, R. G., Russell, C. A., Rivkin, S. E., Culkin, D. J., . . . Crawford, E. D. (1999). Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a southwest oncology group study. J Urol, 161(6), 1823–1825.CrossRef

Posner, M. R., Hershock, D. M., Blajman, C. R., Mickiewicz, E., Winquist, E., Gorbounova, V., . . . Group, T. A. X. Study. (2007). Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med, 357(17), 1705–1715. doi: https://doi.org/10.1056/NEJMoa070956.CrossRef

Vermorken, J. B., Remenar, E., van Herpen, C., Gorlia, T., Mesia, R., Degardin, M., . . . Group, Eortc Tax Study. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695–704. https://doi.org/10.1056/NEJMoa071028.CrossRef

10.

Djajadiningrat RS, Bergman AM, et al. Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer. Clin Genitourin Cancer. 2015;13(1):44–9. https://doi.org/10.1016/j.clgc.2014.06.005.CrossRefPubMed

11.

Bermejo C, Busby JE, Spiess PE, Heller L, Pagliaro LC, Pettaway CA. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol. 2007;177(4):1335–8. https://doi.org/10.1016/j.juro.2006.11.038.CrossRefPubMed

12.

Pagliaro, L. C., Williams, D. L., Daliani, D., Williams, M. B., Osai, W., Kincaid, M., . . . Pettaway, C. A. (2010). Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol, 28(24), 3851–3857. doi: https://doi.org/10.1200/JCO.2010.29.5477.CrossRefPubMedPubMedCentral

13.

Broders AC. Squamous-cell Epithelioma of the skin: a study of 256 cases. Ann Surg. 1921;73(2):141–60.CrossRef

14.

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., . . . Verweij, J. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45(2), 228–247. doi: https://doi.org/10.1016/j.ejca.2008.10.026.CrossRef

15.

Cabanas RM. Anatomy and biopsy of sentinel lymph nodes. Urol Clin North Am. 1992;19(2):267–76.PubMed

16.

Burgers JK, Badalament RA, Drago JR. Penile cancer. Clinical presentation, diagnosis, and staging. Urol Clin North Am. 1992;19(2):247–56.PubMed

17.

Dickstein RJ, Munsell MF, Pagliaro LC, Pettaway CA. Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy. BJU Int. 2016;117(1):118–25. https://doi.org/10.1111/bju.12946.CrossRefPubMed

18.

Ornellas AA, Kinchin EW, Nobrega BL, Wisnescky A, Koifman N, Quirino R. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience. J Surg Oncol. 2008;97(6):487–95. https://doi.org/10.1002/jso.20980.CrossRefPubMed

19.

Graafland NM, van Boven HH, van Werkhoven E, Moonen LM, Horenblas S. Prognostic significance of extranodal extension in patients with pathological node positive penile carcinoma. J Urol. 2010;184(4):1347–53. https://doi.org/10.1016/j.juro.2010.06.016.CrossRefPubMed

20.

Pandey D, Mahajan V, Kannan RR. Prognostic factors in node-positive carcinoma of the penis. J Surg Oncol. 2006;93(2):133–8. https://doi.org/10.1002/jso.20414.CrossRefPubMed

21.

Rosevear HM, Williams H, Collins M, Lightfoot AJ, Coleman T, Brown JA. Utility of (1)(8) F-FDG PET/CT in identifying penile squamous cell carcinoma metastatic lymph nodes. Urol Oncol. 2012;30(5):723–6. https://doi.org/10.1016/j.urolonc.2010.09.015.CrossRefPubMed

22.

Fraley EE, Zhang G, Manivel C, Niehans GA. The role of ilioinguinal lymphadenectomy and significance of histological differentiation in treatment of carcinoma of the penis. J Urol. 1989;142(6):1478–82.CrossRef

23.

Ravi R. Correlation between the extent of nodal involvement and survival following groin dissection for carcinoma of the penis. Br J Urol. 1993;72(5 Pt 2):817–9.CrossRef

24.

Protzel C, Hakenberg OW. Chemotherapy in patients with penile carcinoma. Urol Int. 2009;82(1):1–7. https://doi.org/10.1159/000176016.CrossRefPubMed

25.

Dexeus FH, Logothetis CJ, Sella A, Amato R, Kilbourn R, Fitz K, Striegel A. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol. 1991;146(5):1284–7.CrossRef

26.

Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol. 1998;160(5):1770–4.CrossRef

27.

Hakenberg OW, Nippgen JB, Froehner M, Zastrow S, Wirth MP. Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int. 2006;98(6):1225–7. https://doi.org/10.1111/j.1464-410X.2006.06496.x.CrossRefPubMed

28.

Molife, L. R., Yan, L., Vitfell-Rasmussen, J., Zernhelt, A. M., Sullivan, D. M., Cassier, P. A., . . . Minton, S. (2014). Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol, 7, 1. doi: https://doi.org/10.1186/1756-8722-7-1.CrossRefPubMedPubMedCentral

29.

St George, M., Ayoub, A. T., Banerjee, A., Churchill, C. D., Winter, P., Klobukowski, M., . . . Damaraju, S. (2015). Designing and testing of novel Taxanes to probe the highly complex mechanisms by which Taxanes bind to microtubules and cause cytotoxicity to Cancer cells. PLoS One, 10(6), e0129168. doi: https://doi.org/10.1371/journal.pone.0129168.CrossRefPubMedPubMedCentral

30.

Joerger M. Treatment regimens of classical and newer taxanes. Cancer Chemother Pharmacol. 2016;77(2):221–33. https://doi.org/10.1007/s00280-015-2893-6.CrossRefPubMed

31.

Frederiks CN, Lam SW, Guchelaar HJ, Boven E. Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: a systematic review. Cancer Treat Rev. 2015;41(10):935–50. https://doi.org/10.1016/j.ctrv.2015.10.010.CrossRefPubMed

Title: Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis
Authors: Jian Xu
Gang Li
Shi Miao Zhu
Qi Liang Cai
Zhun Wang
Xiong Yang
Hong Tan Zhang
Yuan Jie Niu
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Metastasis
Penectomy
Penile Cancer
Penile Cancer
Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-019-5847-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Sexuality and cancer in adolescents and young adults - a comparison between reproductive cancer patients and patients with non-reproductive cancer

Correction to: Bioinformatic exploration of OLFML2B overexpression in gastric cancer base on multiple analyzing tools

TIMP-2 secreted by monocyte-like cells is a potent suppressor of invadopodia formation in pancreatic cancer cells

A subtype of oral, laryngeal, esophageal, and lung, squamous cell carcinoma with high levels of TrkB-T1 neurotrophin receptor mRNA

Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer